跳至主要内容
临床试验/NCT06660147
NCT06660147已完成不适用

PAOLA-1 Ancillary Study: Retrospective Validation of KELIM as a Predictive and Prognostic Factor for Maintenance Treatment With PARP Inhibitor After Platinum-Based Chemotherapy in First-Line Ovarian Cancer

ARCAGY/ GINECO GROUP48 个研究点 分布在 2 个国家目标入组 243 人开始时间: 2023年12月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
243
试验地点
48
主要终点
predictive and prognostic value of the KELIM score

研究概览

简要总结

This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit from this treatment

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients randomised in the PAOLA-1 study -

排除标准

  • Opposition to the use of your data for research purposes.

结局指标

主要结局

predictive and prognostic value of the KELIM score

时间窗: 18 months

To evaluate the predictive and prognostic value of the KELIM score in patients receiving maintenance treatment with a PARP inhibitor as part of the PAOLA-1 clinical trial.

次要结局

未报告次要终点

研究者

发起方
ARCAGY/ GINECO GROUP
申办方类型
Other
责任方
Sponsor

研究点 (48)

Loading locations...

相似试验